NR4A1 and breast cancer: In this four-arm trial, 1,803 premenopausal women with hormone receptor positive early stage (stage I-II) breast cancer were randomized to receive goserelin 3.6 mg every 28 days plus either tamoxifen 20 mg daily or anastrozole 1 mg daily, with or without ZOL 4 mg every 6 months for 3 years.